CKAP5 and triple-negative breast carcinoma: Overall, ST8176AA1 compared to T-DM1 appears to exhibit two major advantages: (a) it is in principle applicable for the treatment of triple negative breast cancer; (b) it lacks the intrinsic toxicity of the T-DM1 payload which has been recently reported to be a binder of the cytoskeleton-associated protein 5 on human hepatocytes, a feature that explains off-target toxicity of the ADC in patients (6).